Subscribe
Sign In
Menu
Search
Financial Times
myFT
Search the
FT
Search
Search the
FT
Search
Close
Home
World
US
Companies
Tech
Markets
Climate
Opinion
Lex
Work & Careers
Life & Arts
HTSI
Sign In
Subscribe
Markets
Markets Data
Company Announcements
Financial Times
Close
International Edition
UK Edition
Search the
FT
Search
Top sections
Home
Show more World link
World
Israel-Hamas war
Global Economy
UK
US
China
Africa
Asia Pacific
Emerging Markets
Europe
War in Ukraine
Americas
Middle East & North Africa
Show more US link
US
US Economy
Investing in America
US Companies
US Politics & Policy
US Presidential Election 2024
Show more Companies link
Companies
Energy
Financials
Health
Industrials
Media
Professional Services
Retail & Consumer
Tech Sector
Telecoms
Transport
Show more Tech link
Tech
Artificial intelligence
Semiconductors
Cyber Security
Social Media
Show more Markets link
Markets
Alphaville
Markets Data
Cryptofinance
Capital Markets
Commodities
Currencies
Equities
Wealth Management
Moral Money
ETF Hub
Fund Management
Trading
Climate
Show more Opinion link
Opinion
Columnists
The FT View
The Big Read
Lex
Obituaries
Letters
Lex
Show more Work & Careers link
Work & Careers
Business School Rankings
Business Education
Europe's Start-Up Hubs
Entrepreneurship
Recruitment
Business Books
Business Travel
Working It
Show more Life & Arts link
Life & Arts
Arts
Books
Food & Drink
FT Magazine
House & Home
Style
Travel
FT Globetrotter
Show more Personal Finance link
Personal Finance
Property & Mortgages
Investments
Pensions
Tax
Banking & Savings
Advice & Comment
Next Act
HTSI
Special Reports
FT recommends
Alphaville
FT Edit
Lunch with the FT
FT Globetrotter
#techAsia
Moral Money
Visual and data journalism
Newsletters
Video
Podcasts
News feed
FT Live Events
FT Forums
Board Director Programme
myFT Feed
Portfolio
FT Digital Edition
Crossword
Our Apps
My Account
Sign In
Company Announcements
Latest announcements
Apply
Cancel
Filter announcements by
Company
●
Index
View announcements for companies within...
Dow Jones Industrial Average
FTSE 100
FTSE 250
FTSE 350 ACT
FTSE All Share
FTSE Eurofirst 300
NASDAQ Composite
NYSE Composite
S&P 500
Headline contains
●
Release contains
Date range:
Last 24 hours
Last 7 days
Last 28 days
Last 12 months
Custom date
From
To
Sources:
GlobeNewswire
LSE Regulatory News Service
Business Wire press releases
Canada Wire press releases
PR Newswire press releases
EQS Newswire
Countries:
Filter by country
Austria
Belgium
Bosnia and Herzegovina
Croatia
Cyprus
Estonia
Czech Republic
Finland
Germany
Greece
Hungary
Iceland
Ireland
Italy
Latvia
Lithuania
Luxembourg
Macedonia
Malta
Netherlands
Norway
Poland
Portugal
Romania
Russia
Slovakia
Spain
Sweden
Switzerland
United States
United Kingdom
Turkey
Languages:
Filter by language
Danish
English
Estonian
Finnish
Icelandic
Latvian
Lithuanian
Swedish
Reset filters
Companies:
Index:
Headline contains:
Release contains:
Date range:
Sources:
Countries:
Languages:
Reset filters
Date and time
Company
Headline
Source
01 Jun 2024
CStone Pharmaceuticals
2616:HKG
CStone Announces European Medicine Agency CHMP Recommends Approval of Cejemly® (sugemalimab, anti-PD-L1) as First-Line Treatment for NSCLC
PR Newswire
01 Jun 2024
Genmab A/S
GE9:BER
Biontech SE
BNTX:NSQ
Investigational Acasunlimab (DuoBody® -PD-L1x4-1BB) in Combination with Pembrolizumab Demonstrates Meaningful Clinical Activity in Phase 2 Trial in Patients with Previously Treated Metastatic Non-small Cell Lung Cancer (mNSCLC)
Business Wire
01 Jun 2024
Postmedia Network Canada Corp
PNC.A:TOR
Postmedia Announces Closing of Previously Announced Transaction with the Klein Group
Business Wire
01 Jun 2024
Hyundai Motor Co
HYU:BER
Hyundai Motor America Reports May 2024 Sales
PR Newswire
01 Jun 2024
Nuvation Bio Inc
NUVB WS:NYS
Nuvation Bio Announces Data from Pivotal Phase 2 TRUST-I Study of its Investigational ROS1 Inhibitor, Taletrectinib, are Published in the Journal of Clinical Oncology and Reported at 2024 ASCO Annual Meeting
Business Wire
01 Jun 2024
Jazz Pharmaceuticals PLC
J7Z:FRA
Jazz Pharmaceuticals Presents Overall Survival and Longer Follow-Up Data from HERIZON-BTC-01 Trial Evaluating Zanidatamab in Previously Treated HER2-Positive Biliary Tract Cancer at ASCO 2024
PR Newswire
01 Jun 2024
Eli Lilly and Co
LLY:NYQ
Updated Data from the Phase 1/2 Study of Olomorasib in KRAS G12C-Mutant Advanced Solid Tumors Presented at the 2024 ASCO® Annual Meeting
PR Newswire
01 Jun 2024
Legend Biotech Corp
LEGN:NSQ
Immunocan Launches Innovative Alpaca-derived Nanobody Discovery Platform: ImmuAlpaca® Mouse
PR Newswire
01 Jun 2024
Arcus Biosciences Inc
RCUS:NYQ
Gilead Sciences Inc
GIS:BER
Gilead and Arcus Announce Anti-TIGIT Domvanalimab Plus Zimberelimab and Chemotherapy Exceeded One Year of Median Progression-Free Survival as a First-Line Treatment for Upper GI Cancers
Business Wire
01 Jun 2024
Bristol-Myers Squibb Co
BMY:NYQ
KRAZATI (adagrasib) Demonstrated Statistically Significant Improvement in Progression-Free Survival in Patients with Pretreated Locally Advanced or Metastatic KRASG12C-Mutated Non-Small Cell Lung Cancer
Business Wire
01 Jun 2024
Takeda Pharmaceutical Co Ltd
4502:TYO
Pfizer Inc
PFE:NYQ
Takeda and Pfizer Announce Four-Year Results from Positive Phase 3 HD21 Trial of Additional ADCETRIS® (brentuximab vedotin) Combination in Frontline Hodgkin Lymphoma
Business Wire
01 Jun 2024
Pfizer Inc
PFE:NYQ
Pfizer’s ADCETRIS® Regimen Produces Clinically Meaningful Improvement in Overall Survival in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL)
Business Wire
01 Jun 2024
Gilead Sciences Inc
GIS:BER
Arcus Biosciences Inc
RCUS:NYQ
Gilead and Arcus Announce Anti-TIGIT Domvanalimab Plus Zimberelimab and Chemotherapy Exceeded One Year of Median Progression-Free Survival as a First-Line Treatment for Upper GI Cancers
Business Wire
01 Jun 2024
Summit Therapeutics Inc
SMMT:NMQ
Akeso Inc
9926:HKG.HS
Ivonescimab Manuscript for HARMONi-A Clinical Trial Results Published in JAMA
Business Wire
01 Jun 2024
BioNTech SE
BNTX:NSQ
Phase-2-Daten für Prüfpräparat Acasunlimab (DuoBody® -PD-L1x4-1BB) in Kombination mit Pembrolizumab: Signifikante klinische Aktivität bei vorbehandeltem, metastasiertem nicht-kleinzelligem Lungenkarzinom
GlobeNewswire
01 Jun 2024
Genmab A/S
GE9:BER
Investigational Acasunlimab (DuoBody® -PD-L1x4-1BB) in Combination with Pembrolizumab Demonstrates Meaningful Clinical Activity in Phase 2 Trial in Patients with Previously Treated Metastatic Non-small Cell Lung Cancer (mNSCLC)
GlobeNewswire
01 Jun 2024
BioNTech SE
BNTX:NSQ
Investigational Acasunlimab (DuoBody® -PD-L1x4-1BB) in Combination with Pembrolizumab Demonstrates Meaningful Clinical Activity in Phase 2 Trial in Patients with Previously Treated Metastatic Non-small Cell Lung Cancer (mNSCLC)
GlobeNewswire
01 Jun 2024
Black Diamond Therapeutics, Inc
BDTX:NSQ
Black Diamond Therapeutics Presents Promising BDTX-1535 Clinical Data in Patients with Recurrent Glioblastoma at 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
GlobeNewswire
01 Jun 2024
Akeso Inc
9926:HKG.HS
Ivonescimab in Combination with Chemotherapy Approved in China by NMPA for 2L+ EGFRm NSCLC based on HARMONi-A Clinical Trial: Positive Trend Observed in Overall Survival towards Ivonescimab Plus Chemotherapy
PR Newswire
RNS announcements are delayed by up to an hour.
Fewer results
1
2
3
...
498
499
500
More results